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Gliotoxin, identified from a screen of fungal 
metabolites, disrupts 7SK snRNP, releases P-TEFb, 
and reverses HIV-1 latency
Mateusz Stoszko1, Abdullah M. S. Al-Hatmi2,3,4*, Anton Skriba5*, Michael Roling1*, Enrico Ne1*, 
Raquel Crespo1*, Yvonne M. Mueller6*, Mohammad Javad Najafzadeh2,7*, Joyce Kang8, 
Renata Ptackova5, Elizabeth LeMasters1, Pritha Biswas1, Alessia Bertoldi1,9, Tsung Wai Kan1, 
Elisa de Crignis1, Miroslav Sulc5, Joyce H.G. Lebbink10, Casper Rokx11, Annelies Verbon11, 
Wilfred van Ijcken12, Peter D. Katsikis6, Robert-Jan Palstra1, Vladimir Havlicek5, 
Sybren de Hoog2,3, Tokameh Mahmoudi1†
A leading pharmacological strategy toward HIV cure requires “shock” or activation of HIV gene expression in la-
tently infected cells with latency reversal agents (LRAs) followed by their subsequent clearance. In a screen for 
novel LRAs, we used fungal secondary metabolites as a source of bioactive molecules. Using orthogonal mass 
spectrometry (MS) coupled to latency reversal bioassays, we identified gliotoxin (GTX) as a novel LRA. GTX signifi-
cantly induced HIV-1 gene expression in latent ex vivo infected primary cells and in CD4+ T cells from all aviremic 
HIV-1+ participants. RNA sequencing identified 7SK RNA, the scaffold of the positive transcription elongation 
factor b (P-TEFb) inhibitory 7SK small nuclear ribonucleoprotein (snRNP) complex, to be significantly reduced 
upon GTX treatment of CD4+ T cells. GTX directly disrupted 7SK snRNP by targeting La-related protein 7 (LARP7), 
releasing active P-TEFb, which phosphorylated RNA polymerase II (Pol II) C-terminal domain (CTD), inducing 
HIV transcription.
INTRODUCTION
Combination antiretroviral therapy (cART) causes a drastic and im-
mediate viral decrease by targeting distinct steps in the HIV-1 life 
cycle, effectively blocking replication and halting disease progression 
(1–3). However, cART does not target or eliminate HIV that persists 
in a latent state in cellular reservoirs. Because some of the proviruses 
are replication competent, latent HIV-infected cells inevitably rebound 
once cART is interrupted, leading to necessity for lifelong therapy 
(4). Particularly in resource-limited countries, which are also dispro-
portionally affected, this is translated into an insurmountable med-
ical, social, and financial burden. To achieve a scalable cure for HIV 
infection, it will be necessary to reduce or eliminate the latent HIV- 
infected reservoir of cells and/or equip the immune system with the 
robustness and effectiveness necessary to prevent viral rebound such 
that cART can be safely discontinued.
An important breakthrough in HIV-1 cure was the unequivocal 
proof that it is possible to mobilize the latent patient HIV reservoir 
by treatment with agents that activate HIV gene expression [latency 
reversal agents (LRAs)] (5). However, clinical studies thus far have 
shown little to no reduction in the latent reservoir in patients (6, 7). 
This is consistent with limited potency and specificity of currently 
tested drugs, which appear to be unable to reach a significant pro-
portion of latently infected cells or to induce HIV-1 expression in 
latent reservoir at sufficient levels to produce viral proteins for rec-
ognition by the immune system (8). Furthermore, transcriptional 
stochasticity and heterogeneity of latent HIV integrations (9) may 
pose additional barriers to reactivation of the latent reservoir as a 
whole; sequential rounds of stimulation yield new infectious parti-
cles (10), while certain LRA combinations result in more efficient 
latency reversal when administered in intervals rather than at once 
(11). In addition, pleiotropic functions and toxic effects of LRAs may 
compromise the ability of CD8+ T cells to eliminate HIV protein–
expressing cells (12, 13). Therefore, it is critical to identify and 
develop novel therapeutics, which strongly induce HIV-1 gene ex-
pression to effectively disrupt HIV latency without dampening the 
immune response.
The pharmaceutical industry is highly equipped for high- throughput 
screens using defined synthetic libraries. While this is an effective 
approach, it is important to record that approximately half of the 
novel small molecules introduced to the market between 1981 and 
2014 are natural or nature-derived (14). Biological systems represent 
an invaluable source of functional molecules with high chemical di-
versity and biochemical specificity, evolved during millions of years of 
adaptation. In particular, fungi represent a largely unexplored source 
of compounds with potential therapeutic use. Fungi secrete a gamut 
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of extracellular compounds and other small molecular extrolites (15). 
While some of these compounds have been shown to have antibiotic 
(ex. penicillin) or carcinogenic (ex. aflatoxin) properties, little is 
known in general about their biological activities and possible mo-
lecular targets. In addition, a single fungal strain often produces 
a wide array of secondary metabolites that are not essential for its 
growth but are exuded as a consequence of specific environment, such 
as nutrient-rich versus minimal growth conditions (16, 17). Fungal 
extrolites might target various signaling pathways in mammalian 
cells, such as those influencing HIV-1 gene expression. Fungal super-
natants are an ideal source for an expert academic setting, where 
low- and medium-throughput biological screening systems, academ-
ic knowledge of evolutionary mycology, and state-of-the-art frac-
tionation and purification techniques are routinely combined. Studies 
of regulation of HIV-1 gene expression have identified distinct mo-
lecular mechanisms and cellular pathways at play, which can be tar-
geted pharmacologically to activate expression of latent HIV (18, 19). 
The rich diversity of fungal extrolites therefore may prove an un-
tapped source of new compounds that target HIV for reactivation. In 
search of novel LRAs, here, we have performed an unbiased medium- 
throughput screen of fungal extrolites, coupled to HIV latency 
reversal bioassays and orthagonal fractionation and mass spectrom-
etry (MS)/nuclear magnetic resonance (NMR), and identified glio-
toxin (GTX). GTX potently reversed HIV-1 latency in multiple 
in vitro latency models as well as ex vivo in cells obtained from all 
aviremic HIV-1–infected patients examined without associated cyto-
toxicity. We demonstrate that GTX disrupts the positive transcrip-
tion elongation factor (P-TEFb)–sequestering 7SK small nuclear 
ribonucleoprotein (snRNP) complex by targeting the La-related pro-
tein 7 (LARP7) component, leading to degradation of its scaffold 
7SK RNA and release of active P-TEFb, which is then recruited by 
Tat to phosphorylate the Ser2 residue of the RNA polymerase II 
(Pol II) C-terminal domain (CTD) and activate HIV transcription 
elongation. Our data highlight the power of combining a medium- 
throughput bioassay, mycology, and orthogonal MS to identify novel 
potentially therapeutic compounds.
RESULTS
Growth supernatant of Aspergillus fumigatus identified 
in a medium-throughput screen of fungal secondary 
metabolite has HIV-1 latency reversal activity
We screened 115 species of filamentous fungi for their ability to in-
duce HIV-1 proviral expression; of the species that appeared prom-
ising, 2 to 4 additional strains were tested (table S1). The species 
belonged to 28 orders (43 families) of the fungal kingdom (Fig. 1A) 
and were chosen on the basis of their evolutionary position, ecolog-
ical trends, and known active production of extracellular compounds. 
The majority of fungi were of ascomycetous affinity, four species 
were of basidiomycetous affinity, and two belonged to the lower 
fungi. Selected fungi were grown in both complete yeast media and 
minimal media (RPMI 1640), as they are known to produce distinct 
extrolites depending on their growth conditions (fig. S1). Culture 
supernatants were then screened for latency reversal activity using 
Jurkat-derived 11.1 and A2 cell line models of HIV-1 latency (J-Lat) in 
a low-medium throughput assay setup, in which expression of green 
fluorescent protein (GFP) is controlled by the HIV-1 promoter and in-
dicates latency reversal. We identified the supernatant of Aspergillus 
fumigatus CBS 542.75 to strongly activate the latent HIV-1 5′ long 
terminal repeat (LTR) (Fig. 1B). We also compared other Aspergillus 
species growth supernatants indicated for their potential to induce 
HIV-1 expression (Fig. 1C) and observed that only strains of A. 
fumigatus (CBS 542.75, CBS 113.26, and CBS 100074) had latency 
reversal activity (Fig. 1C).
Orthogonal liquid chromatography–MS/NMR strategy 
coupled to latency reversal bioassays identifies GTX 
from growth supernatant of A. fumigatus as a putative LRA
Because of the chemical complexity of the positive fungal superna-
tants, direct MS analysis of their constituents proved to be impossi-
ble. Therefore, A. fumigatus CBS 100074 growth supernatant was 
fractionated several times by means of orthogonal MS (Fig. 1D). We 
selected this particular supernatant as it showed the highest potency to 
reverse latency in the J-Lat models. After each round of fractionation, 
all samples/fractions were again tested in latency reversal bioassays, 
followed by quantitation of the GFP expression and identification 
of fractions retaining latency reversal activity. As expected, original-
ly less active fractions became more active during the fractionation/
enrichment process (Fig. 1E). The most active 7B/7C fractions were 
further fractioned on a hydrophilic-lipophilic balance (HLB) car-
tridge (11 samples) and components of 7B/7C and 11C fractions 
dereplicated by CycloBranch software (Fig. 1E and fig. S2, A and B) 
(20). Compound matching against the annotated database of Asper-
gillus secondary metabolites revealed a set of candidate compounds 
further selected for latency reversal testing (fig. S2C and table S2). 
Among the candidate molecules identified, GTX, obtained from a 
commercially available synthetic source, was able to induce expres-
sion of the latent provirus in a concentration-dependent manner 
(Fig. 1F). Notably, GTX was found in all positive fractions (table S2). 
While GTX isolated from supernatant of CBS 100074 showed strong 
induction of HIV-1 transcription, supernatant of Aspergillus flavus 
(CBS 625.66), a close relative of A. fumigatus that was inactive in 
latency reversal (Fig. 1C), did not contain GTX (fig. S2, D and E), 
providing further support that GTX is the main mediator of LRA 
activity in A. fumigatus supernatants.
GTX reverses latency in ex vivo infected primary CD4+ T cells 
without associated cytotoxicity
To examine the latency reversal potential of GTX in a more clinically 
relevant system, we used a modified primary ex vivo infected latency 
model, in which primary CD4+ T cells are infected with a full-length 
replication-incompetent HIV-1 virus driving expression of the lu-
ciferase reporter (fig. S3A) (21). Treatment of latently infected 
CD4+ T cells with GTX resulted in significant, concentration- 
dependent latency reversal at lower concentrations than necessary 
to achieve reactivation in latently infected cell lines (Fig. 2, A to C). 
GTX (20 nM) treatment resulted in more than 20-fold induction of 
HIV-1 expression (Fig. 2A), which translated into more than 10% 
latency reversal of that observed upon maximal stimulation with 
phorbol 12-myristate 13-acetate (PMA)/ionomycin (Fig. 2B). Simi-
lar to the latency reversal observed using commercially available 
synthetic GTX (Fig. 2, A and B), treatment of HIV-1–infected latent 
primary CD4+ T cells with GTX isolated from growth supernatant 
of A. fumigatus CBS 100074, estimated at 20 nM by NMR in com-
parison to commercially available GTX, resulted in significant la-
tency reversal, approximately 10% of maximal PMA/ionomycin 
stimulation (Fig. 2C). At high concentrations, GTX is known to 
be toxic to immune cells (22–24), ascribed to its unusual disulfide 
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Fig. 1. Medium-throughput screen of fungal secondary metabolites combined with orthogonal fractionation and MS strategy coupled to latency reversal 
bioassays identifies GTX from growth supernatant of A. fumigatus to reverse HIV-1 latency. (A) Phylogenetic tree representing the main orders of the fungal 
kingdom with strains used in the current study, collapsed per order. Orders selected from the tree published (57), with some of the lower orders included for structural 
reasons. Approximate ecological trends in the orders are summarized by symbols, as follows:  vertebrate pathogenicity prevalent,  climatic extremotolerance 
prevalent,  frequent production of extracellular metabolites or mycotoxins,  frequent osmotolerance or growth in sugary fluids,  numerous members with 
soilborne lifestyle,  numerous members inhabiting decaying wood rich in hydrocarbons,  frequent insect association,  frequent mushroom decomposition or 
hyperparasitism on fungi or lichens, and  frequent inhabitants of foodstuffs or vertebrate intestinal tracts. (B) Latency reversal bioassay performed by treatment of 
J-Lat A2 cells with increasing volumes of growth [normalized by O.D. (optical density)] supernatants obtained from selected fungal strains. (C) Latency reversal bioassay 
in J-Lat A2 cells with growth supernatants obtained from members of the Aspergillus genus. Cells were treated as in (B). (D) Schematic representation of the orthogonal 
MS strategy coupled to latency reversal bioassays used to identify putative LRA. See main text for full description. (E) Three preconcentration cartridges (HLC, SCX, and 
MAX) were combined with variable content of extracting solvent (A: 5% MeOH, B: 45% MeOH, and C: 95% MeOH; FT, flowthrough). Latency reversal potential of fraction-
ated secondary fungal metabolites was tested via treatment of J-Lat A2 cells. Latency reversal (fold increase percentage of GFP, left axis, black bars) and cell viability 
(percentage of viability, right axis, empty bars) were assessed by flow cytometry analysis. (F) Commercially obtained versions of five common molecules identified in ac-
tive fractions were tested for LRA activity in J-Lat A2 cells. Data are presented as fold increase percentage of GFP expression and percentage of viability as indicated, ±SD 
from at least three independent experiments.
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bridge, and responsible for pleiotropic effects on cellular and viral 
systems (25).
Consistent with the literature, GTX concentrations upward of 
100 nM induced significant toxicity as indicated by annexin V stain-
ing (Fig. 2D and fig. S3B). However, primary CD4+ T cell viability 
was not significantly affected after GTX treatment at concentrations 
up to 20 nM, with moderate toxicity observed at 50 nM (Fig. 2D and 
fig. S3B). Thus, at lower concentrations in which GTX did not show 
toxicity on CD4+ T cells, strong latency reversal was induced (Fig. 2, 
A to D, and fig. S3B). CD8+ T cells play a central role in eliminating 
HIV-infected cells (26). Therefore, it is of utmost importance to eval-
uate the potential toxicity of newly developed LRAs on CD8+ T cells 
(13). GTX at a low concentration of 20 nM did not reduce the via-
bility or proliferation capacity of CD8+ T cells whether unstimulated 
or CD3/CD28-stimulated peripheral blood mononuclear cells 
(PBMCs) were examined (Fig. 2, E and F, and fig. S4, A and B). 
Consistent with the literature (22–25), treatment with higher con-
centrations of GTX at 100 nM and 1 M caused apoptosis and death 
of primary CD4+ and CD8+ T cells as well as B cells, natural killer 
(NK) cells, and monocytes, as shown by annexin V staining followed by 
flow cytometry (Figs. 2, D and E, and 3C and figs. S3B and S4, A to C). 
Potential for clinical applicability of a candidate LRA also requires that 
it does not induce global T cell activation nor should it interfere with 
CD8+ T cell activation. Treatment of unstimulated primary CD4+ T cells 
and CD8+ T cells with GTX (20 nM), which significantly reversed 
latency, did not induce expression of the T cell activation markers 
CD69 and CD25 (Figs. 2G and 3D and fig. S5, A and B), nor did it 
induce proliferation of resting CD4+ and CD8+ T cells (fig. S5, C 
and D), while, as expected, PMA/ionomycin treatment activated T cells 
(Fig. 2G). Conversely, GTX treatment of activated PBMCs also did 
Fig. 2. GTX (20 nM) reverses HIV-1 latency in ex vivo infected primary CD4+ T cells without associated cytotoxicity, T cell activation, or inhibition of proliferative 
capacity. (A) Latency reversal after treatment of latently infected primary CD4+ T cells with increasing concentrations of GTX for 24 hours as indicated, shown as fold in-
duction over untreated control luciferase activity. Statistical analysis was calculated using Kruskal-Wallis one-way analysis of variance (ANOVA) (****P < 0.0001). (B) Data 
presented in (A) normalized and shown as percent latency reversal activity relative to treatment with PMA/Ionomycin. (C) Latency reversal after treatment of HIV-1– 
infected latent primary CD4+ T cells with 20 nM GTX isolated from growth supernatant of A. fumigatus CBS 100074, measured as increased luciferase activity normalized 
to and shown as percentage of activation of PMA/ionomycin (n = 6). Wide horizontal lines represent average, and shorter horizontal lines represent SD. (D) Viability of the 
primary CD4+ T cells treated for 24 (red line) and 48 (green line) hours with indicated increasing concentrations of GTX, assessed by flow. (E) Unstimulated or CD3/CD28- 
stimulated PBMCs were treated with 20 and 100 nM GTX for 72 hours, stained with AnnexinV, and cell death (AnnexinV+ CD3+CD8+) was determined by flow cytometry. 
Treatment-specific cell cytotoxicity was calculated as indicated in the Materials and Methods section. Each symbol represents one healthy donor (n = 6), and horizontal 
lines depict means. (F) Representative fluorescence-activated cell sorting (FACS) plot overlay showing the proliferation of unstimulated or CD3/CD28-stimulated CD8+ 
T cells in the presence or absence of GTX. Cells were stained with a proliferation dye and analyzed 72 hours later by flow cytometry to define nonproliferating cells (pro-
liferation dye undiluted, bright stain intensity) and dividing cells (proliferation dye diluted, reduced stain intensity). (G) Activation status of primary CD4+ T cells upon GTX 
treatment as indicated (n = 6).
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not inhibit CD25 expression (Fig. 3D and fig. S5, A and B) or pro-
liferation of activated CD4+ or CD8+ T cells (fig. S5, C and D).
GTX enhances activity of other LRA class molecules 
and synergizes strongly with histone deacetylase and  
BAF inhibitors
To investigate possible synergies, we tested the latency reversal po-
tential of GTX (20 nM) in combination with a panel of known LRAs in 
the J-Lat A2 and 11.1 models of latency (fig. S6) as well as in ex vivo 
infected primary CD4+ T cells (Fig. 3, A and B). GTX cotreatment 
enhanced the latency reversal activity observed after single treat-
ments with all compounds (Fig. 3, A and B). When latent HIV-1–
infected primary CD4+ T cells were cotreated with GTX (20 nM) 
and either the histone deacetylase (HDAC) inhibitor suberoylanilide 
hydroxamic acid (SAHA) or BAF (BRG1- or BRM-associated factors) 
inhibitors caffeic acid phenethyl ester (CAPE) [at 1 M concentra-
tion in which it does not inhibit nuclear factor B (NF-B)] (27) or 
BRD-K98645985 (28), synergistic reversal of HIV-1 latency was ob-
served (Fig. 3, A and B). Cotreatments with BET (bromodomain 
and extra-terminal proteins) inhibitors JQ-1 and OTX-015, as well 
Fig. 3. GTX strongly synergizes with HDAC and BAF inhibitors and reverses latency in primary CD4+ T cells obtained from all tested aviremic participants. (A and 
B) HIV-1 latency reversal in latent ex vivo HIV-1–infected primary CD4+ T cells in response to 24-hour cotreatment with 20 nM GTX and distinct LRA class compounds 
[2 nM RMD, 350 nM SAHA, 1 M CAPE, 2 M OTX-01, 0.5 M JQ-1, and 0.2 M prostratin (A) and 1 M CAPE and 5 M BRD-K98645985 (B)] and shown as fold increase in 
luciferase activity. S indicates compound synergism in latency reversal according to the Bliss independence score. (C) Cytotoxicity of GTX alone and combined with indi-
cated LRAs in CD4+ T cells. Unstimulated or CD3/CD28-stimulated PBMCs were cotreated as indicated for 72 hours followed by annexin V staining, and cell death 
(AnnexinV+ CD3+CD4+) was determined by flow cytometry. (D) GTX (20 nM) does not alter activation of CD4+ T cells. PBMCs from healthy donors were incubated with the 
indicated LRAs for 72 hours, either unstimulated or stimulated with CD3/CD28 antibodies. Panels depict pooled data showing the frequency of CD25+ cells within CD4+ 
T cells. (E) Absolute, cell-associated (CA) pol copy number in CD4+ T cells isolated from five aviremic participants that were treated in vitro with vehicle control (Untr), GTX 
(20 and 40 nM), or positive control for 24 hours as indicated. Statistical significance was calculated using t test (*P < 0.05; **P < 0.005; ***P < 0.0005). ns, not significant. 
(F) Data presented in (D) had been averaged and plotted together. Each symbol represents aviremic participant: green, participant 1; blue, participant 2; white, participant 
3; yellow, participant 4; and pink, participant 5. Statistical significance was calculated using unpaired Mann-Whitney test (*P < 0.05).
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as prostratin, resulted in an additive effect on HIV-1 provirus ex-
pression. In the primary CD4+ T cell model of HIV-1 latency, GTX 
treatment alone showed more potent latency reversal activity than 
SAHA, CAPE, OTX-015, JQ-1, or romidepsin (RMD) alone at test-
ed noncytotoxic concentrations (Fig. 3, A and B). RMD treatment 
showed modest latency reversal activity (Fig. 3A) and, consistent 
with the literature (13), significant CD4+ and CD8+ T cell cytotoxic-
ity (Fig. 3C and fig. S4, A and B). With the exception of RMD, we 
did not observe any negative impact of these cotreatments on via-
bility and proliferation of CD4+ T cells (Fig. 3C and fig. S5C), CD8+ 
T cells (figs. S4, A and B, and S5D), and other immune subpopula-
tions, including CD19+ B cells, CD56+ NK cells, and CD14+ mono-
cytes (fig. S4C). Moreover, none of the cotreatments altered the 
activation status of either resting or activated CD4+ and CD8+ T 
cells (Fig. 3D and fig. S5, A and B). Our observed synergistic ef-
fects upon GTX cotreatment with BAF inhibitors and the HDAC 
inhibitor SAHA suggested that GTX may target a different pathway 
for HIV-1 latency reversal, as targeting the same pathway with dif-
ferent molecules would more likely result in additive effects. Un-
like SAHA, GTX treatment of CD4+ T cells did not result in increased 
histone acetylation (fig. S7A). Similarly, we excluded that GTX be-
haves as a protein kinase C (PKC) agonist, as treatment with GTX 
did not induce T cell activation or the expression of PKC pathway 
target genes (Fig. 2G and fig. S7B).
GTX reverses HIV-1 latency after ex vivo treatment of CD4+  
T cells from all aviremic HIV-1–infected study participants
We next examined the potential of GTX to reverse latency after 
ex vivo treatment of CD4+ T cells obtained from people living with 
HIV-1. All five participants enrolled were treated with cART and 
maintained HIV-1 viremia below 50 copies/ml for at least 2 years. 
Despite differences in the size of the latent pool, assessed by maximal 
stimulation of the cells with -CD3/CD28 beads or PMA/ionomycin, 
GTX treatment at noncytotoxic 20 and 40 nM concentrations sig-
nificantly increased the levels of cell-associated HIV-1 pol RNA 
copies (CA-pol copies) in CD4+ T cells obtained from aviremic 
HIV-1+ participants (Fig. 3, E and F). Notably, the observed GTX 
effect is systematic, as latency reversal was uniformly observed in 
cells of all tested participants after 24 hours of stimulation (Fig. 3, 
E and F). This observed latency reversal at the RNA level is the first 
step consistent with induction of protein expression, although this 
is not formally examined here. In addition, we observed no increase 
in expression of genes related to T cell–specific responses, reactive 
oxygen species, or apoptosis, previously reported pleiotropic effects 
of GTX observed at significantly higher concentrations (fig. S7C). 
These results therefore indicate that GTX treatment at nontoxic con-
centrations reverses latency without inducing immune cell toxicity 
or activation and without affecting T cell proliferation, rendering 
GTX a promising potential candidate for further clinical investiga-
tion in context of HIV-1 latency reversal and inclusion in “shock 
and kill” strategies.
GTX reverses HIV-1 latency via disruption of 7SK snRNP, 
leading to release of active P-TEFb
To gain insight into the molecular mechanism by which GTX re-
verses latency, we performed RNA sequencing of primary resting 
CD4+ T cells isolated from healthy blood donors that were treated 
for 4 hours with 20 nM GTX. This short incubation time was cho-
sen to focus on primary effects of GTX on the global transcriptome, 
decreasing the presence and likelihood of secondary transcriptional 
effects. We observed a very good correlation between treatments of 
two independent healthy blood donors (Fig. 4A, top). Moreover, less 
than 700 genes showed an altered differential expression pattern 
(Fig. 4A, bottom). Small nuclear RNA 7SK was the most decreased 
(more than ninefold) transcript after GTX treatment in CD4+ T cells 
from the independent donors (Fig. 4, A and B). 7SK RNA serves as 
a scaffold for the 7SK snRNP complex that sequesters the P-TEFb 
and inhibits its activity (29–33). Among all components of the 7SK 
snRNP complex and its close interactors, only the 7SK transcript 
was affected by treatment with GTX (Fig. 4B and fig. S9A). Consist-
ent with our observations after treatment of CD4+ T cells obtained 
from aviremic participants (fig. S7C), we did not detect significant 
change in expression of NF-B, oxidative stress, apoptosis, and T cell 
effector function-related genes after GTX treatment (figs. S7B and 
S8), indicating that GTX (20 nM) treatment does not influence 
these pathways after 4 or 24 hours of stimulation. As P-TEFb is an 
essential cofactor for Tat-mediated HIV-1 transcription elongation 
(34, 35), we examined whether GTX treatment affects P-TEFb ac-
tivity. Phosphorylation of Ser2 residues within the CTD of RNA Pol 
II is a prerequisite for activation of transcription elongation and is 
mediated by the kinase activity of cyclin-dependent kinase 9 (CDK9), 
a component of P-TEFb (36). To examine whether GTX treatment 
resulted in Ser2 RNA Pol II phosphorylation, we treated resting 
CD4+ T cells with GTX, the CDK9 inhibitor flavopiridol (FPD), and 
PMA or CD3/CD28 as positive control (Fig. 4C and fig. S9B). As 
expected, FPD treatment abrogated RNA Pol II phosphorylation, 
while PMA stimulation led to strong Ser2 RNA Pol II phosphoryla-
tion. Treatment with GTX caused an increase in phosphorylation of 
the CDK9 target RNA Pol II Ser2 in three independent donors tested 
(Fig. 4, C and D, and fig. S9B). We also examined potential Tat- 
independent effects of GTX on basal HIV-1 transcription by com-
paring GTX-induced reactivation in J-Lat A72 cells, which lack Tat, 
with that in J-Lat A2 cells (fig. S9C). While GTX robustly reactivated 
transcription in Tat-containing A2 cells, in comparison, A72 cells were 
not significantly reactivated. These results support a Tat-dependent 
mechanism of GTX function consistent with a role in enhancing 
Tat–P-TEFb–mediated HIV-1 transcription.
The fact that short-term GTX treatment enhanced P-TEFb ac-
tivity in resting CD4+ T cells without cellular activation (Figs. 2G, 
3D, and 4C) led us to hypothesize that GTX treatment may cause 
destabilization of the 7SK snRNP complex, leading to the release of 
free (active) P-TEFb. Active P-TEFb would then become available 
for transcription elongation at the latent HIV-1 LTR, a critical step 
required for HIV-1 latency reversal (37–39). To test this, we per-
formed glycerol gradient sedimentation experiments after treatment 
of resting CD4+ T cells with GTX (Fig. 4, E to G, and fig. S9D). GTX 
treatment (20 nM) of CD4+ T cells for 4 hours resulted in release of 
free P-TEFb from its inhibitory higher–molecular weight 7SK snRNP 
complex, as shown by Western blot analysis depicting distribution 
of the P-TEFb component CDK9 over high– and low–molecular 
weight fractions (Fig. 4F and fig. S9D). As expected, control treat-
ment of CD4+ T cell lysates with ribonuclease A (RNase A), which 
digests the 7SK RNA scaffold, resulted in release of free P-TEFb, which 
eluted at lower–molecular weight fractions (Fig. 4F and fig. S9D). Quan-
tification of free versus 7SK snRNP–sequestered P-TEFb demonstrates 
a significant GTX-induced release of free P-TEFb from the 7SK snRNP 
complex in CD4+ T cells from three independent donors (Fig. 4G). 
CDK9 T-loop phosphorylation at Thr186 is critical for the kinase 
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activation and its dissociation from the 7SK snRNP (40). In resting 
CD4+ T cells, cyclin T1 levels are low, as are the levels of CDK9 T-loop 
phosphorylation (39). To check whether GTX- induced release 
of P-TEFb involves increased CDK9 T-loop phosphorylation or increase 
in cyclin T1 levels, we treated primary CD4+ T cells with increasing 
concentrations of GTX for 6 hours and used PMA as positive con-
trol. At 6 hours after treatment, at a time point in which we observe 
phosphorylation of RNA Pol II CTD (Fig. 4, C and D), GTX treat-
ment does not cause phosphorylation of CDK9 at Thr186, nor does 
it lead to increased cyclin T1 levels (fig. S9, E and F), demonstrating 
that these mechanisms are not involved in GTX-induced latency 
reversal at this early time point.
To understand better which component of the 7SK snRNP com-
plex may be targeted by GTX, we performed in silico docking ex-
periments using two independent software packages, Chimera and 
Achilles. We modeled GTX against all essential components of the 
complex separately, as complete crystal structure of 7SK snRNP is 
not yet available. Notably, we observed preferential binding of GTX 
Fig. 4. GTX treatment of resting CD4+ T cells causes decrease in 7SK RNA and activation of P-TEFb activity. (A) Heatmap of differentially expressed genes obtained 
from RNA sequencing analysis of primary CD4+ T cells treated as indicated for 4 hours (top). RNA sequencing indicates 7SK RNA to be the most differentially decreased 
gene in response to GTX treatment of CD4+ T cells in two independent donors (bottom). (B) GTX treatment of primary CD4+ T cells for 4 hours leads to specific depletion 
of 7SK RNA levels and not mRNA levels of other components of the 7SK snRNP complex. (C) Representative Western blot (WB) analysis of CTD Ser2 phosphorylation of RNA 
Pol II mediated by CDK9 in primary CD4+ T cells treated for 6 hours with GTX as indicated. PMA was used as a positive control, and FPD was used as a negative control. 
(D) Quantification of bands representing phosphorylated RNA Pol II normalized to tubulin and relative to untreated control from three independent experiments (C; 
fig. S9C). Statistical significance was calculated using unpaired t test (*P < 0.05; **P < 0.01). (E and F) GTX treatment causes release of P-TEFb from sequestration within the 
7SK snRNP complex. (E) Schematic of glycerol gradient experiments, in which cell lysates (from GTX-treated or untreated cells) are loaded on top of generated glycerol 
gradients (10 to 30%) and ultracentrifuged, followed by collection of fractions, trichloroacetic acid protein precipitation, and subsequent analysis by SDS–polyacrylamide 
gel electrophoresis Western blotting. (F) Representative Western blot analysis of glycerol gradient sedimentation of lysates from primary CD4+ T cell, which were treated 
(6 hours) with GTX (20 nM) or vehicle control as indicated using antibodies specific for the P-TEFb component CDK9. As control, untreated lysates were treated with RNase 
for 1 hour to digest 7SK RNA and release P-TEFb. (G) Quantification of free versus total CDK9 in primary CD4+ T cells treated as indicated, as shown in (F) and fig. S9E, from 
three independent donors. Statistical significance was calculated using unpaired t test (*P < 0.05).
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into the hydrophobic pocket of LARP7, which, in physiological 
conditions, is responsible for binding stem loop 4 (SL4) of the 7SK 
RNA (Fig. 5, A and B, and fig. S10). LARP7 is a critical component, 
responsible for stabilization of the 7SK snRNP complex, as its de-
pletion has been shown to lead to decreased levels of 7SK RNA 
with concomitant increase in free P-TEFb levels (41). To test 
whether GTX interferes with LARP7-7SK RNA binding, we per-
formed a 7SK RNA release assay (Fig. 5, C to F). 75K snRNP com-
plex was immunoprecipitated and immobilized on protein G beads 
using a LARP7 antibody. 7SK snRNP–bound beads were then ei-
ther left untreated or treated with GTX or RNase A as indicated, 
and the presence of LARP7-bound CDK9 was examined by West-
ern blot analysis of the bead-bound fraction (Fig. 5, D and E). As 
expected, RNase A treatment resulted in direct disruption of the 
75K snRNP complex as measured by release of the CDK9 compo-
nent into the supernatant and its separation from the bead-bound 
LARP7 component (Fig. 5, D and E). GTX treatment also resulted in 
release of CDK9 as observed in relative decrease in LARP7-bound 
Fig. 5. GTX disrupts 7SK snRNP, causing release of P-TEFb and enhanced HIV-1 transcription. (A) Crystal structure of human LARP7 CTD in complex with 7SK RNA 
SL4 (Protein Data Bank ID code 6D12). LARP7 is shown in space-filling representation (gray) with bound RNA as yellow cartoon representation with bases indicated as flat 
rings (oxygen in red). (B) Proposed binding mode of GTX into the deep pocket on the surface of LARP7 as predicted by Chimera’s AutoDock Vina function and the Achilles 
Blind Docking server. Color code for GTX: carbon (turquoise), oxygen (red), sulfur (yellow), hydrogen (white), and nitrogen (blue). (C) Schematic representation of the 7SK 
snRNP coimmunoprecipitation CDK9 release experiment. (D) 7SK snRNP complex is immunoprecipitated using beads coated with anti-LARP7. Beads are divided and left 
either untreated or treated with GTX 20 nM or 1 M or RNase A as indicated. Bead-bound fractions are separated and subjected to Western blot analysis to detect presence 
of LARP7 and CDK9. IgG, immunoglobulin G. (E) Quantification of CDK9 abundance normalized to immunoprecipitated LARP7 and relative to untreated control (n = 3). 
Statistical significance was calculated using unpaired t test (*P < 0.05; **P < 0.01). (F) 7SK RNA release assay from immunoprecipitated 7SK snRNP complex, as represented 
in (C). Bound and released fractions are subjected to reverse transcription quantitative polymerase chain reaction to quantitate the levels of bead-bound and released 
7SK RNA in reaction supernatant. Input 7SK RNA (prereaction beads) was used for normalization. Statistical significance was calculated with unpaired t test (n = 3, 
**P < 0.01; ***P < 0.001; n.d., not detected). (G) Proposed model for GTX-mediated transcription activation of the latent HIV-1 LTR via degradation of 7SK RNA and release 
of CDK9 from the 7SK snRNP complex. Free P-TEFb is then recruited to the HIV-1 Tat-TAR axis, leading to phosphorylation of RNA Pol II at Ser2 and subsequent stimulation 
of transcription elongation.
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CDK9 as determined by Western blot analysis (Fig. 5, D and E). 
In agreement, treatment with GTX resulted in a concomitant signifi-
cant decrease in abundance of scaffold 7SK RNA from the bead-bound 
7SK snRNP fraction as well as an approximately sixfold increase in 
levels of 7SK RNA in the released fraction (Fig. 5F).
Our experimental data, together with this modeling exercise and 
previously published data, are consistent with a model in which GTX 
interferes with the binding of SL4 of 7SK RNA into the hydrophobic 
pocket of LARP7, which results in destabilization of the complex 
and subsequent release of P-TEFb and 7SK RNA (Fig. 5, D to G). In 
resting CD4+ T cells, 7SK RNA is then degraded and free P-TEFb 
made available for recruitment to the paused RNA Pol II at the latent 
HIV LTR by the Tat-TAR (trans-activation response element) 
axis. CDK9 then phosphorylates CTD of RNA Pol II, leading to ac-
tivation of proviral transcription elongation (Fig. 5G).
DISCUSSION
Distinct classes of LRAs have been shown to target different sub-
populations of proviruses (9, 19, 42, 43). Thus far, none of the clin-
ically tested LRAs have been able to induce strong viral expression 
or to significantly deplete the latent reservoir in patients, pointing to 
potential limitations of single treatments (6, 7). The heterogeneous 
nature of latent HIV integrations and the complex molecular mech-
anisms that contribute to maintaining HIV latency, together with 
individual genetic variability, dictate that a cocktail of stimulatory com-
pounds targeting distinct cellular and HIV gene regulatory pathways 
would be most effective to activate the latent reservoir in HIV-1– 
infected patients (19). Preclinical studies demonstrate that combi-
nation treatments can result in synergism and lead to stronger HIV-1 
latency reversal (11, 19, 27, 28, 44–48). Here, we found that GTX, a 
molecule that targets the HIV-1 transcription elongation step, strongly 
synergized with LRAs that derepress chromatin structure, namely, 
BAF and HDAC inhibitors, which respectively target complexes 
that position the latent LTR chromatin in a repressive configuration 
(49) or deacetylate histones compacting LTR chromatin. Cotreatment 
of primary latently infected CD4+ T cells with GTX and BET inhib-
itors resulted in additive and not synergistic increase in HIV tran-
scription. This observation is consistent with the fact that these 
compounds target the same mechanistic step: transcription elonga-
tion at the HIV-1 LTR. Our data highlight the attractiveness of simul-
taneous pharmacological targeting of mechanistically distinct steps 
in HIV-1 transcription regulation, namely, at the level of chromatin 
structure, transcription factor–induced activation and transcrip-
tion elongation. We postulate that more robust latency reversal will 
be observed when compounds targeting these three mechanistic 
steps are combined, and further optimized by interventions that ad-
dress blocks occurring posttranscriptionally, at the polyadenylation 
and splicing stages, which may hinder translation of HIV-1 genes (38). 
In addition, consistent with the importance of targeting transcrip-
tion elongation, shown recently to be a major rate-limiting step in 
HIV-1 latency reversal in patient CD4+ T cells (38), ex vivo GTX 
treatment of CD4+ T cells obtained from cART-suppressed avi-
remic HIV-1–infected patients demonstrated significant increase in 
levels of cell-associated HIV-1 RNA in all patients examined.
GTX causes disruption of the 7SK snRNP complex with subse-
quent release of active P-TEFb by directly targeting LARP7. Other 
molecules including HMBA (hexamethylene bisacetamide) (50) and 
DRB (5,6-Dichloro-1-β-d ribofuranosylbenzimidazole) and acti-
nomycin D (30, 32) have also previously been shown to cause 7SK 
snRNP disruption although through indirect mechanisms. Given 
the significance of P-TEFb in HIV transcription elongation and the 
current lack of available molecules able to mediate its release from 
the inhibitory 7SK snRNP complex, GTX may be a promising can-
didate not only in the context of HIV-1 latency reversal but also in 
other diseases in which P-TEFb plays a prominent regulatory role 
(51). Our modeling exercises provide insight toward a mechanism 
where GTX competes with 7SK RNA for the hydrophobic pocket of 
LARP7, causing destabilization and disassembly of the 7SK snRNP 
complex, leading to the release of P-TEFb and subsequent degrada-
tion of the 7SK RNA scaffold as observed in our experiments (Figs. 4 
and 5 and figs. S9 and S10). LARP7 has been shown to be a critical 
scaffold required for the stability of the 7SK snRNP complex; con-
sistent with our observations, RNA interference–mediated depletion 
of LARP7 resulted in elevated levels of free P-TEFb and increased 
Tat-mediated HIV-1 expression, concomitant with degradation of 
7SK RNA (41).
Thus far, GTX has been regarded as a toxin and a virulence factor 
of Aspergillus spp. fungi, shown to function as an immunosuppressant 
that inhibits phagocytosis, blocks NF-B signaling and cytokine pro-
duction, and induces reactive oxygen species formation (22, 24, 25, 52–55). 
These properties are ascribed to the molecule’s unusual disulfide bridge, 
which may mediate the activity of GTX by cycling between a re-
duced and oxidized state (25). However, it is important to note that 
all of the above-mentioned effects of GTX were observed at high con-
centrations in the 100 nM to 5 M range, concentrations at which 
we also observed significant toxicity and cell death (Fig. 2 and figs. 
S3, S4, and S6). Serum concentrations of GTX reported in patients 
with aspergillosis are found to be between 200 nM and 2.4 M (56), 
more than 10 to 100 orders of magnitude higher than concentrations 
that we have shown to effectively reverse HIV-1 latency in primary 
T cells and cells of cART-suppressed HIV-1–infected participants 
(Figs. 3 and 4). Together, these observations suggest that lower GTX 
concentrations in the 20 nM range, at which effective HIV-1 latency 
reversal is observed in primary CD4+ T cells without associated tox-
icity, global T cell activation, or interference with capacity for CD8+ 
T cells activation, will be physiologically achievable in a therapeutic 
context. Our data therefore support the potential of GTX for inclu-
sion in combination latency reversal therapeutic approaches in a 
safe concentration range. Last, our data underlie the power of cou-
pling a screen of fungal extrolites, which comprise a largely unex-
plored plethora of bioactive chemical entities, with bioassays and 
state-of-the-art fractionation and MS/NMR as a strategy to identify 
and characterize novel compounds with therapeutic potential.
MATERIALS AND METHODS
Cells and culture conditions
Jurkat latent (J-Lat) cell lines A2 and 11.1 were cultured in RPMI 
1640 media supplemented with 10% fetal bovine serum (FBS) and 
penicillin-streptomycin (100 g/ml) at 37°C in a humidified 95% 
air–5% CO2 incubator. Primary CD4+ T cells were cultured in RPMI 
1640 media supplemented with 7% FBS and penicillin-streptomycin 
(100 g/ml) at 37°C in a humidified 95% air–5% CO2 incubator.
Preparation of fungal supernatants
We screened 115 species of filamentous fungi (table S1 and fig. S1A). 
The species belonged to 28 orders (43 families) of the fungal kingdom. 
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The majority were of ascomycetous affinity including ascomycetous 
yeasts (Saccharomycetales: 4 species), 12 were of basidiomycetous 
affinity including 3 basidiomycetous yeasts (Trichosporonales and 
Tremellales) and 3 species of lower fungi (Mucorales) (57). Rationale 
for choice was the expected production of a wide array of metabolites, 
which are known to be more pronounced in fungi living in habitats 
with environmental stress or microbial competition. Particularly 
versatile nutrient scavengers in Eurotiales and Hypocreales are 
established metabolite and toxin producers. Onygenales are cellu-
lose and keratin degraders and contain a large cluster of mammal 
pathogens with alternating environmental life cycles. Members of 
Capnodiales are saprobes in environments with stressful micro-
climates such as rock, glass, and indoor. Identity of all strains was 
verified by recombinant DNA internal transcribed spacer and par-
tial nucLSU (D1/D2 of large subunit) sequencing. Strains were de-
rived from lyophilized storage in the reference collection of the 
Centraalbureau voor Schimmelcultures (housed at the Westerdijk 
Fungal Biodiversity Institute, Utrecht, The Netherlands). After open-
ing, contents of vials were taken up in 1 ml of malt peptone and 
distributed on Malt Extract Agar (MEA; Oxoid) culture plates. 
Strains were maintained on MEA slants and subcultured regularly 
until use. Mycelial fragments of 1-week-old colonies grown on MEA 
at 25°C were used as inocula for 500-ml flasks containing 150 ml of 
RPMI 1640 (with glutamine), shaken at 180 rpm and incubated at 
25°C for 7 days, with one negative control. Flasks were checked daily 
until biomass reached one-third to one-fourth of the volume and then 
harvested by centrifugation at 14,000g and filtered using 0.2-m 
metal filters. Supernatants were transferred to Falcon tubes and used 
for latency screens. One strain per genus was used in a first round; 
additional isolates, some of which were close relatives and others 
located at larger phylogenetic distance, were tested in case of posi-
tive response. Positive tests of strain A. fumigatus CBS 113.26 was 
thus followed by A. fumigatus CBS 154.89, CBS 117884, and CBS 
100074, Aspergillus lentulus CBS 117884, and A. flavus CBS 625.66.
Fractionation and MS characterization of active components
Complex fungal supernatants (3.3 ml) were twice extracted with 
ethylacetate (3 ml) in glass tubes (5-min vortex) and centrifuged at 
3000 rpm. Water phase was discarded and organic extract dried in 
a vacuum concentrator. Lipids were removed by consequent hexane/ 
water extraction [50/50 (v/v), 4-ml total volume], and aqueous 
phase was collected and dried. The dried material was reconstituted 
in 50% methanol (MeOH) and such a solution loaded onto HLB, 
MCX (Mixed-mode, strong Cation-eXchange), and MAX (Mixed-
mode, strong Anion-eXchange) cartridges (Fig. 2, A and B) ob-
tained from Waters Corporation (Prague, Czech Republic). The 
adsorbed compounds were desalted and stepwise eluted with in-
creasing (5, 45, and 95%) organic solvent (MeOH) gradient (1% 
HCOOH), providing A, B, and C sample variants, respectively 
(Fig. 2B). HLB was based on N-vinylpyrrolidone–divinylbenzene 
copolymer and provided 5 fractions. MCX was a cation-exchange 
sorbent that represented the HLB material modified with SO3H− 
groups (6 fractions). The best performance was provided by anion- 
exchange MAX cartridge, providing 7 fractions. After each round 
of fractionation, all samples were tested in J-Lat/S-Lat latency mod-
els, followed by quantitation GFP/luciferase expression and identi-
fication of fraction-retaining activating component. As expected, 
originally less active fractions have become positive, as the active 
components became populated during the enrichment process. 
The same phenomenon was observed when working with less or 
more active Aspergillus strains (fig. S2B). The most active 7B/7C 
fractions were further fractioned on HLB cartridge (11 samples) 
and components dereplicated by CycloBranch software (20). Com-
pound matching against the annotated database of Aspergillus 
secondary metabolites has revealed a set of candidate compounds 
further selected for latency reversal testing. GTX was present in 
active fractions (Fig. 2B and fig. S2B). Detailed examination of 
commercial (GTX, Cayman and ApexBio) and natural GTXs was 
performed by high-performance liquid chromatography and Fourier 
transform ion cyclotron resonance (FTICR) MS. A solariX XR 12T 
FTICR instrument (Bruker Daltonics, Billerica, USA) was operated 
in a positive ion mode with electrospray ionization. Separation of 
GTX components was performed on an Acquity UPLC HSS T3 an-
alytical column (Waters, Prague, Czech Republic) with 1.0 mm by 
150 mm dimensions and 1.8-m particle size. The analysis was 
carried out at 30°C and a 30 l/min flow rate with the following 
A/B gradient: 0 min, 30% B; 30 min, 95% B; 40 min, 95% B; 50 min, 
30% B; 60 min, 30% B. The gradient components A and B were rep-
resented by 0.1% formic acid in water or acetonitrile (ACN), re-
spectively. One-minute time windows around S2 and S3/S4 GTXs 
were used for fraction isolation. The preparative chromatography 
was performed both with commercial GTX and with A. fumigatus 
100074 strain.
Flow cytometry and annexin V staining
GFP expression of cell lines J-Lat A2 and 11.1 and phenotype of spin- 
infected primary CD4+ T cells at the moment of reactivation were 
analyzed by fluorescence-activated cell sorting (FACS) as described 
previously (27). For annexin V staining, 106 cells were washed with 
phosphate-buffered saline (PBS) supplemented with 3% FBS and 
2.5 mM CaCl2 and stained with annexin V–PE (phycoerythrin) (Becton 
and Dickinson) for 20 min at 4°C in the dark in the presence of 2.5 mM 
CaCl2. Stained cells were washed with PBS/FBS/CaCl2, fixed with 
1% formaldehyde, and analyzed by FACS.
Primary CD4+ T cell isolation and infection
Primary CD4+ T cells were isolated from buffy coats from healthy 
donors by Ficoll gradient (GE Healthcare) followed by negative se-
lection with RosetteSep Human CD4+ T Cell Enrichment Cocktail 
(STEMCELL Technologies). Isolated cells were left overnight for re-
covery and used for spin infection according to Lassen and Greene 
method as described previously (27, 58). Briefly, CD4+ T cells were 
infected with the pNL4.3.Luc.R-E- virus by spinoculation (120 min 
at 1200g) and cultured for 3 days in RPMI 1640, 10% FBS, and 
penicillin- streptomycin (100 g/ml) in the presence of saquinavir 
mesylate (5 M). Three days after infection, cells were treated as 
indicated in the presence of raltegravir (30 M). Cells were harvested 
24 hours after treatment, and luciferase activity was measured using 
the Luciferase Assay System (Promega, Leiden, The Netherlands). 
Infections were performed using pseudotyped particles obtained 
by cotransfecting HXB2-Env with pNL4.3.Luc.R-E- plasmid into 
human embryonic kidney 293T cells using polyethylenimine 48 
and 72 hours after transfection, and supernatants containing 
pseudotyped virus were collected, filtered with a 0.45-m filter, and 
stored at −80°C. Molecular clones pNL4.3.Luc.R-E- and HIV-1 
HXB2-Env and antiretroviral drugs saquinavir mesylate and 
raltegravir were provided by the Centre for AIDS Reagents, National 
Institute for Biological Standards and Control. HIV-1 molecular 
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clone pNL4.3.Luc.R-E- and HIV-1 HXB2-Env expression vectors 
were donated by N. Landau and by K. Page and D. Littman, 
respectively.
HIV-1 latency reversal in primary CD4+ T cells isolated 
from aviremic patients
Primary CD4+ T cells were isolated as described previously (27). Three 
million CD4+ T cells were plated in triplicate at a cell density of 106/ml 
and treated as indicated. After 24 hours, cells were lysed, and total 
RNA was isolated as described below. Written informed consent 
was obtained from all patients involved in the study. The study was 
conducted in accordance with ethical principles of the Declaration 
of Helsinki. The study protocol and any amendment were approved 
by The Netherlands Medical Ethics Committee (MEC-2012-583).
Total RNA isolation and quantitative reverse transcription 
polymerase chain reaction
Cells were lysed in TRI reagent, and RNA was isolated with the Total 
RNA Zol-Out kit (A&A Biotechnology); complementary DNA (cDNA) 
synthesis and quantitative polymerase chain reaction (qPCR) was 
performed as described previously (27). Gene expression was calcu-
lated using the 2−Ct method (59), and expression of glyceraldehyde 
phosphate dehydrogenase (GAPDH) was used for normalization. 
Absolute quantification of cell-associated pol RNA was performed 
as described previously (27). Briefly, qPCR was performed in a final 
volume of 25 l using 4 l of cDNA, 2.5 l of 10× PCR buffer (Life 
Technologies), 1.75 l of 50 mM MgCl2 (Life Technologies), 1 l of 
10 mM deoxynucleotide triphosphates (Life Technologies), 0.125 l 
of 100 M Pol forward primer (HXB2 genome 4901 → 4924), 0.125 of 
100 M Pol reverse primer (HXB2 genome 5060 → 5040), 0.075 l 
of 50 M of Pol probe, and 0.2 l of Platinum Taq polymerase (Life 
Technologies). The lower limit of detection of this method was of 
20 copies of HIV-1 RNA in1 g of total RNA. The absolute number 
of pol copies in PCR was calculated using standard curves ranging 
from 7 to 480 copies of a plasmid containing the full-length HIV-1 
genome (pNL4.3.Luc.R-E-). The amount of HIV-1 cell-associated 
RNA was expressed as the number of copies per microgram of input 
RNA in reverse transcription. Preparations of cell-associated RNA 
were tested for potential contamination with HIV-1 DNA and/or 
host DNA by performing the PCR amplification in the presence and 
absence of reverse transcriptase.
Primers used for reverse transcription (RT)–qPCR were as fol-
lows: pol forward, 5′GGTTTATTACAGGGACAGCAGAGA3′ and 
pol reverse, 5′ACCTGCCATCTGTTTTCCATA3′; pol probe, [6FAM] 
AAA ATT CGG TTA AGG CCA GGG GGA AAG AA[BHQ1]; 
tumor necrosis factor– (TNF) forward, 5′TAGGCTGTTCCCAT-
GTAGCC3′ and TNF reverse, 5′CAGAGGCTCAGCAATGAGTG3′; 
interleukin-2 (IL-2) forward, 5′ACCTCAACTCCTGCCACAAT3′ 
and IL-2 reverse, 5′GCACTTCCTCCAGAGGTTTG3′; IFN for-
ward, 5′ATAATGCAGAGCCAAATTGTCTCC3′ and IFN re-
verse, 5′ATGTCTTCCTTGATGGTCTCCAC3′; CD25 forward, 
5′ATCAGTGCGTCCAGGGATAC3′ and CD25 reverse, 5′GAC-
GAGGCAGGAAGTCTCAC3′; BAK1 (Brassinosteroid Insensitive 
1-associated receptor kinase 1)  forward, 5′GGTTTTCCGCAGC-
TACGTTTTT3′ and BAK1 reverse, 5′GCAGAGGTAAGGTGAC-
CATCTC3′; BAX (BCL-2-associated X protein) forward, 
5′CCCGAGAGGTCTTTTTCCGAG3′ and BAX reverse, 5′CCAG-
CCCATGATGGTTCTGAT3′; BCL2 (B-Cell lymphoma 2 protein) 
forward, 5′GGTGGGGTCATGTGTGTGG3′ and BCL2 reverse, 
5′CGGTTCAGGTACTCAGTCATCC3′; CASP-3 (Caspase-3 
protein) forward, 5′CATGGAAGCGAATCAATGGACT3′ and 
CASP-3 reverse, 5′CTGTACCAGACCGAGATGTCA3′; AKT1 
(RAC-alpha serine/threonine-protein kinase) forward, 5′AGC-
GACGTGGCTATTGTGAAG3′ and AKT1 reverse, 5′GCCAT-
CATTCTTGAGGAGGAAGT3′; NRF2 (NFE2-related factor 2 
protein) forward, 5′TTCCCGGTCACATCGAGAG3′ and NRF2 
reverse, 5′TCCTGTTGCATACCGTCTAAATC3′; FOXO3a for-
ward, 5′CGGACAAACGGCTCACTCT3′ and FOXO3a reverse, 
5′GGACCCGCATGAATCGACTAT3′; KEAP1 (Kelch-like ECH- 
associated protein 1)  forward, 5′GCAATGAACACCATCCGAAGC3′ 
and KEAP1 reverse, 5′ACCATCATAGCCTCCAAGGAC3′; CYCT1 
(Cyclin T 1 protein) forward, 5′GGCGTGGACCCAGATAAAG3′ 
and CYCT1 reverse, 5′CTGTGTGAAGGACTGAATCAT3′; 
CDK9 forward, 5′ATGGCAAAGCAGTACGACTCG3′ and CDK9 
reverse, 5′GCAAGGCTGTAATGGGGAAC3′; GAPDH forward, 
5′CAAGAAGGTGGTGAAGCAG3′ and GAPDH reverse, 5′GC-
CAAATTCGTTGTCATACC3′; and B2M forward, 5′ATGAG-
TATGCCTGCCGTGTG3′ and B2M reverse, 5′CCAAATGCGG-
CATCTTCAAAC3′.
Glycerol gradient sedimentation
Glycerol gradients were prepared as described previously (50). Brief-
ly, around 40 × 106 primary CD4+ T cells isolated from healthy do-
nors were either untreated or treated with GTX (20 nM) for 4 hours 
for RNase A treatment. Cells were lysed for 30 min in buffer A sup-
plemented either with RNasin (100 U/ml; Promega) for untreated and 
GTX conditions or with RNase A (100 g/ml). RNase-supplemented 
lysates were incubated for 10 min at room temperature to ensure 
efficient degradation of RNA. Lysates were fractionated by centrif-
ugation in a SW41 Ti rotor at 38,000 rpm for 20 hours. Fractions 
(1 ml) were collected in 2-ml tubes and subjected to trichloroacetic 
acid (TCA) precipitation of proteins as described previously (60). 
Briefly, to each 1 ml of fraction, 110 l of ice-cold 100% TCA was 
added and incubated on ice for 10 min. Then, 500 l of ice-cold 10% 
TCA was added to each sample and incubated on ice for 20 min, 
followed by centrifugation at 20,000g for 30 min. Supernatants were 
carefully removed, and precipitates were gently washed with 500 l 
of ice-cold acetone followed by centrifugation at 20,000g for 10 min. 
Supernatants were gently removed and dried at room temperature 
for about 10 min. Protein precipitates were then resuspended in 50 l 
of Laemmli loading buffer and subjected to 10% SDS–polyacrylamide 
gel electrophoresis (SDS-PAGE) separation and detection of CDK9 
(C-20, sc-484, Santa Cruz Biotechnology).
RNA Pol II and CDK9 T-loop phosphorylation
For RNA Pol II phosphorylation, 10 million primary CD4+ T cells 
were either untreated or treated with GTX, OTX-015 (1 M), FPD 
(500 nM), PMA (10 nM), or CD3/CD28 beads (cell:bead ratio of 1:1) 
for 6 hours. For CDK9 phosphorylation, 5 million primary CD4+ 
T cells were either untreated or treated with GTX (20 and 40 nm) or 
PMA (10 nM) for 6 hours. Four million cells were lysed for 30 min 
on ice with immunoprecipitation buffer [25 mM Hepes (pH 7.9), 
150 mM KCl, 1 mM EDTA, 5 mM MgCl2, 5% glycerol, 1% NP-40, 
0.5 mM dithiothreitol (DTT), PhosSTOP phosphatase inhibitor 
(Sigma-Aldrich), and a cOmplete protease inhibitor cocktail (Sigma- 
Aldrich)] and subjected to Western blot analysis using the following 
antibodies: total  RNA Pol II  (N-20, sc-899, Santa Cruz Biotechnology), 
phospho-Ser2 RNA Pol II  (H5, ab-24758, Abcam), CDK9 (C-20, sc-484, 
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Santa Cruz Biotechnology) (Fig. 4C and fig. S9B), total CDK9 (D7, 
sc-13130, Santa Cruz Biotechnology) (fig. S9E), cyclinT1 (H-245, sc-
10750, Santa Cruz Biotechnology), -tubulin (ab6160, Abcam), and 
phospho-CDK9 Thr186 (#2549, Cell Signaling Technology).
7SK snRNP complex immunoprecipitation and  
7SK RNA / CDK9 release assay
Fifty million Jurkat cells were lysed in 5 ml of immunoprecipitation 
buffer [1% NP-40, 25 mM tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 
5% glycerol, and EDTA-free protease inhibitor cocktail (1 U/ml; 
Roche)] for 30 min on ice and centrifuged for 10 min at 14,000 rpm. 
Protein G Sepharose beads (200 l) were washed two times with 
lysis buffer. Lysates were incubated with beads and 2 g of antibody 
against human LARP7 (A303-723A, Bethyl Laboratories) at 4°C over-
night. Next day, the beads were washed two times with lysis buffer, 
resuspended in 400 l of lysis buffer containing 1 mM DTT, and 
divided in four reactions of 100 l each. The presence of DTT is crit-
ical to the activity of GTX in agreement with its lability and known 
unusual disulfide bridge. Aliquotes were left untreated or treated 
with GTX for 1 hour or with RNase A for 15 min at room tempera-
ture. Next, supernatant was discarded, and beads were washed twice 
with lysis buffer. Beads were resuspended in 100 l of Laemmli load-
ing buffer and subjected to 12% SDS-PAGE separation and detec-
tion of CDK9 (sc-484, Santa Cruz Biotechnology) and LARP7 by 
Western blot. Ten microliters of beads suspension before and after 
treatment and 10 l of supernatant after treatment were taken and 
resuspended in TRI reagent (Sigma) for subsequent RNA isolation 
(Total RNA Zol-Out kit, A&A Biotechnology). cDNA was synthe-
tized using 10 l of RNA solution as described above and diluted 
560 times for quantitative RT-PCR. 7SK RNA was amplified using 
specific primers described elsewhere (61). qPCR was performed as 
described above. Values were normalized to the input RNA (post-
treatment bead suspension).
Histone acetylation
Ten million primary CD4+ T cells were treated with GTX concen-
tration gradient, SAHA, or left untreated for 4 hours and then 
washed twice in PBS. Cells were lysed for 10 min at 4°C in TBE 
(Tris-borate-EDTA) buffer [PBS, 0.5% Triton X-100 (v/v), 2 mM 
phenylmethylsulfonyl fluoride, and 0.02% (w/v) NaN3] at a density 
of 107 cells per 1 ml of the buffer. Samples were centrifuged at 425g 
for 10 min at 4°C. Supernatants were discarded, and cell pellets 
were washed in half the volume of TEB buffer used for lysis and 
centrifuged as before. Supernatants were discarded, and pellets 
were resuspended in 0.2 N HCl at a density of 4 × 107 cells/ml. His-
tones were extracted overnight at 4°C and then centrifuged at 425g 
for 10 min at 4°C. Supernatants were collected, protein concentra-
tion was determined by Bradford assay, and samples were subjected 
to SDS-PAGE Western blot. The following antibodies were used in 
Western blot analysis: anti–acetyl-histone H4 (06-598, Millipore) 
and anti-histone H2B (ab52484, Abcam).
RNA sequencing and data analysis
Ten million primary CD4+ T cells were stimulated with 20 nM GTX 
or left unstimulated for 4 hours. Experiment was performed in du-
plicate on cells isolated from two buffy coats from healthy donors as 
described above. RNA was isolated as described above. cDNA li-
braries were generated using the Illumina TruSeq Stranded mRNA 
Library Prep kit (Illumina). The resulting DNA libraries were se-
quenced according to the Illumina TruSeq Rapid v2 protocol on an 
Illumina HiSeq 2500 sequencer. Reads were generated of 50 base 
pairs in length. Reads were mapped against the GRCh38 human ref-
erence using HiSat2 (version 2.0.4). We calculated gene expression 
values using htseq-count (version 0.6.1) using Ensembl transcript 
annotation. Heatmaps were generated using MORPHEUS (https://
software.broadinstitute.org/morpheus/index.html).
Toxicity assay
PBMCs were isolated by density gradient centrifugation (Ficoll- 
Hypaque, GE Healthcare Life Sciences) from buffy coats from healthy 
donors (Sanquin, Amsterdam) and either used immediately or frozen in 
freezing media [90% FBS/10% dimethyl sulfoxide (DMSO] and stored 
short term at −80°C. For cytotoxicity testing, cells were cultivated in 
culture media RPMI 1640 (Life Technologies) supplemented with 10% 
FBS, 2 mM l-glutamine, penicillin (100 U/ml), and streptomycin- 
sulfate (100 g/ml) at a concentration of 1 × 106 cells/ml in 24-well 
plates (Thermo Scientific) that were either uncoated (unstimulated 
cells) or coated with anti-human CD3 (1 g/ml; clone UCHT1, no 
azide/low endotoxin, BD Biosciences) and anti-CD28 (10 g/ml; 
clone CD28.2, no azide/low endotoxin, BD Biosciences) monoclonal 
antibodies (stimulated cells). PMA/ionomycin was added at 50 ng/ml 
and 1 g/ml, respectively, and cells were exposed for 16 hours. The 
following LRAs were added at the concentrations indicated in fig-
ures: GTX (ApexBio), SAHA-Vorinostat (Selleck Chemicals), CAPE 
(MP Biomedicals), and RMD (Sigma-Aldrich). LRAs at indicated con-
centrations were added to the cultures, and cells were continuously 
exposed for 72 hours. Since GTX was reconstituted in ACN and all 
other LRAs in DMSO, both solvents were added to the DMSO/
ACN control culture (ACN, 1:10000; DMSO, 1:2500) to control for 
the effect that these solvents may have on cell viability.
Flow cytometry for cytotoxicity assay
To examine the effects the LRAs have on immune cell subpopulations, 
cell viability, activation, and proliferation were analyzed by flow 
cytometry. To determine the cytotoxic effect of the LRAs on cells, 
AnnexinV staining was used to define apoptotic and dead cells. Sur-
face antigens were detected by incubating 0.8 to 1.0 × 106 cells with 
predetermined optimal concentrations of monoclonal antibody mixes 
in FACS wash [FW; Hank’s Balanced Salt Solution (Life Technolo-
gies), 3% FBS (Life Technologies), 0.02% NaN3, and 2.5 mM CaCl2] 
for 20 min at 4°C, washed one time with FW, and fixed with 1% 
paraformaldehyde. To determine proliferation, cells were stained with 
0.07 M CellTrace Far Red Cell Proliferation dye according to the 
manufacturer’s protocol (Thermo Fisher Scientific) before cultivating 
for 72 hours with either unstimulated or stimulated conditions in the 
presence of LRA. Upon cell division, the proliferation dye intensity 
decreases in daughter cells, and this was measured by flow cytome-
try. The following directly conjugated monoclonal anti-human anti-
bodies were used to analyze CD8+ T cells (CD3+CD8+), CD4+ T cells 
(CD3+CD4+), B cells (CD3−CD19+), monocytes (CD14+), and NK 
cells (CD3−CD56+): CD3-BV421 (clone UCHT1), CD4-BV650 (SK3), 
CD8-BV786 (RPA-T8), CD14-PE-Cy7 (61D3, eBioscience), CD19-
PerCP-Cy5.5 (HIB19, eBioscience), CD56-PE-Cy5.5 (CMSSB, 
eBioscience), annexin V–PE, and CD25− Super Bright 600 (BC96, 
eBioscience). All antibodies were purchased from BD Biosciences 
unless otherwise indicated. Between 2 × 105 and 4 × 105 events were 
collected per sample within 24 hours after staining on a LSRFortessa 
(BD Biosciences, 4 lasers, 18 parameters) and analyzed using FlowJo 
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software (version 9.7.4, Tree Star). Data are represented as frequen-
cy within a defined population. Treatment-specific cell cytotoxicity 
was calculated using the following formula: [(% drug-induced cell 
death − % cell death in DMSO/ACN only)/(100 − % cell death in 
DMSO/ACN only)]*100.
Molecular docking
Molecular docking was used to predict the most likely binding mode 
of GTX to LARP7 CTD. The crystal structure of human LARP7 
CTD in complex with 7SK RNA SL4 [Protein Data Bank (PDB) 
ID code 6D12] was optimized using PDB-REDO (62) and used as a 
template to define the receptor for the docking simulation. The re-
sulting pdb file was manually adapted for input into the docking 
procedure by elimination of protein chain B and RNA domain C 
and replacement of selenium atoms (present as selenomethionin, 
incorporated for phasing purposes) (63) by sulfur. GTX ligand 
structure was built and energy minimized using the program 
Chimera (64). Molecular docking of GTX to LARP7 CTD was per-
formed using the Achilles Blind Docking server (https://bio-hpc.
ucam.edu/achilles/) and Chimera’s AutoDock Vina function (65). 
The resulting solutions were ranked on the basis of the highest 
binding affinity (or lowest binding energy). Figures were created 
using PyMol software (66).
Quantification and statistical analysis
Western blot quantification
Differential band density was quantified by ImageQuant TL software 
using area and profile-based toolbox. For glycerol gradient Western 
blot quantification, an area frame was defined for all bands (total 
CDK9 protein content in all fractions), and complex-bound CDK9 
bands (heavy fractions) or free CDK9 bands (light fractions) were 
defined. The three area frames were measured for total density after 
background subtraction (local average). Relative complex-bound CDK9 
or free CDK9 percentage was calculated regarding the untreated con-
trol (total CDK9 abundance). For RNAPII Ser2 phosphorylation, 
CDK9 T-loop phosphorylation, or immunoprecipitation Western 
blot quantification, an area for each respective band and loading con-
trols were defined, and total density was measured after background 
subtraction (local average). LARP7 abundance was first normalized 
to total CDK9 abundance for each lane, and relative abundance was 
calculated regarding untreated control. RNAPII Ser2 abundance was 
first normalized to tubulin abundance for each lane, and relative 
abundance was calculated with respect to untreated control. Thr186 
P-CDK9 and cyclin T1 band density was normalized to total CDK9 
abundance, and relative abundance was calculated with respect to 
untreated control.
Statistical significance
Statistical significance was calculated as indicated in the figure 
legends. Analyses were performed using Prism version 7.03 (GraphPad 
software).
Data and code availability
Sequencing data that support the findings of this study were depos-
ited in Gene Expression Omnibus and are available under the acces-
sion code GSE135184.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/33/eaba6617/DC1
View/request a protocol for this paper from Bio-protocol.
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